Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Business Strategies M & A

Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies

Executive Summary

Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba

You may also be interested in...



Deal Watch: Gurnet Point, Novo Holdings Buy Out Paratek

Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.

Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio

AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.

Tibsovo Gets A Win In AML Following Servier Takeover

Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Deals Business Strategies M & A
Latest Headlines

Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges

Chinese RNA Therapy Developers Extend Fundraising Streak Into December

AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel

Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo

See All
UsernamePublicRestriction

Register

SC143134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By